Carlo Vancheri

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts

Enrico Conte, Elisa Gili, Evelina Fagone et al. · European Journal of Pharmaceutical Sciences · 2014 · 359 citations

Veterinary Medicine, Pharmacology, Pharmacotherapy +11

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

Peter M. George, Paolo Spagnolo, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2020 · 346 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

Carlo Vancheri, Michael Kreuter, Luca Richeldi et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 297 citations

Medicine, Pharmacology, Pharmacotherapy +13

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Andreas Günther, Ekaterina Krauss, Silke Tello et al. · Respiratory Research · 2018 · 259 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +9